Syon Capital LLC Purchases Shares of 4,807 Edwards Lifesciences Co. (NYSE:EW)

Syon Capital LLC purchased a new stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,807 shares of the medical research company's stock, valued at approximately $356,000.

Several other hedge funds also recently added to or reduced their stakes in EW. MGO One Seven LLC lifted its stake in Edwards Lifesciences by 16.3% during the fourth quarter. MGO One Seven LLC now owns 6,658 shares of the medical research company's stock worth $493,000 after purchasing an additional 931 shares in the last quarter. Dark Forest Capital Management LP lifted its stake in Edwards Lifesciences by 224.3% during the fourth quarter. Dark Forest Capital Management LP now owns 10,404 shares of the medical research company's stock worth $770,000 after purchasing an additional 7,196 shares in the last quarter. Eversept Partners LP acquired a new position in Edwards Lifesciences during the fourth quarter worth $12,635,000. Nippon Life Global Investors Americas Inc. lifted its stake in Edwards Lifesciences by 7.0% during the fourth quarter. Nippon Life Global Investors Americas Inc. now owns 69,450 shares of the medical research company's stock worth $5,141,000 after purchasing an additional 4,570 shares in the last quarter. Finally, Senator Investment Group LP acquired a new position in Edwards Lifesciences during the fourth quarter worth $36,275,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded down $0.24 during midday trading on Thursday, reaching $75.26. The company's stock had a trading volume of 1,019,462 shares, compared to its average volume of 4,985,847. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock's 50 day simple moving average is $71.03 and its 200 day simple moving average is $71.23. The firm has a market capitalization of $44.24 billion, a PE ratio of 10.79, a P/E/G ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. During the same quarter last year, the business posted $0.66 earnings per share. The business's revenue for the quarter was up 6.2% on a year-over-year basis. On average, equities research analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on EW. Wolfe Research cut Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Piper Sandler upgraded Edwards Lifesciences from a "neutral" rating to an "overweight" rating and raised their price target for the company from $73.00 to $80.00 in a research note on Thursday, April 24th. Morgan Stanley raised their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 12th. Stifel Nicolaus upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating and raised their price target for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Finally, Evercore ISI cut their price target on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of "Hold" and a consensus price target of $79.45.

Insider Activity

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. The trade was a 26.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.75, for a total value of $492,375.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company's stock, valued at $3,555,402. This trade represents a 12.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,853 shares of company stock worth $5,163,062 over the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.